Myriad Genetics traded at $20.57 this Thursday February 2nd, increasing $0.63 or 3.13 percent since the previous trading session. Looking back, over the last four weeks, Myriad Genetics gained 34.76 percent. Over the last 12 months, its price fell by 16.30 percent. Looking ahead, we forecast Myriad Genetics to be priced at 19.70 by the end of this quarter and at 17.83 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
20.57
Daily Change
3.13%
Yearly
-16.30%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Agilent 155.36 -0.09 -0.06% 9.57%
Accelerate Diagnostics 0.73 0.05 7.44% -74.06%
Becton, Dickinson and Co. 248.35 -5.82 -2.29% -8.22%
Bio-Rad Laboratories 480.85 7.43 1.57% -22.80%
Biocept 0.55 0.003 0.60% -79.35%
Bruker 72.40 1.04 1.45% 7.86%
Quest Diagnostics 145.57 -3.07 -2.07% 6.79%
Danaher 271.46 3.96 1.48% -6.36%
Exact Sciences 70.75 2.64 3.87% -5.79%
Standard Biotools Inc 2.01 0.01 0.50% -38.53%
Hologic 84.40 1.62 1.96% 15.05%
Illumina 223.37 6.85 3.16% -37.37%
J&J 165.54 0.62 0.38% -4.18%
Mettler Toledo International 1,585.25 24.71 1.58% 6.00%
Myriad Genetics 20.57 0.63 3.13% -16.30%
NanoString Technologies 12.53 1.18 10.35% -64.03%
OraSure Technologies 5.55 0.21 3.84% -38.39%
Pacific Biosciences Of California 11.90 0.42 3.66% 11.63%
PerkinElmer 144.54 5.27 3.78% -23.09%
Quidel 91.39 2.88 3.25% -8.32%
Repligen 195.36 4.57 2.39% -1.51%
Thermo Fisher Scientific 588.34 0.98 0.17% -1.11%
Veracyte 27.80 1.84 7.09% 0.32%
Waters 344.37 6.34 1.88% 4.79%

Indexes Price Day Year
USND 12201 310.63 2.63% -12.09%

Myriad Genetics
Myriad Genetics, Inc. (Myriad) is a genetic testing and precision medicine company. Myriad is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. It operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to determine the risk of developing disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can progress patient care. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services, such as finance, human resources, legal and information technology. The Company's products include myRisk, BRACAnalysis, BRACAnalysis CDx myChoice CDx, Prolaris, EndoPredict, Foresight and Prequel.